Global Healthcare CMO Market: Trends & Opportunities (2015-2020)
Scope of the Report
This report named “Global Healthcare CMO Market: Trends & Opportunities (2015-2020)”, analyses the growth and sizing of global healthcare CMO market and its segments. This report provides the analysis of global healthcare CMO market by value and by segment.
The analysis of global medical device CMO market is done by value, by players and by cost structure and analysis of global pharmaceutical CMO is done by value and by segments. The global pharmaceutical CMO market by segments is analyzed in detail by providing analysis of each of its segment.
This report includes the analysis of global active pharmaceutical ingredient CMO market by value and analysis of finished dosage formulation CMO market by value, by revenue structure, by geographical approach and by dosage formulation.
This report also provides the analysis of global pharmaceutical CDMO market. This analysis includes the global pharmaceutical CDMO market by value, by players and by geography. The regional analysis of global pharmaceutical CDMO market is also done in this report. The regions included are United States of America, Europe, China and India.
This report also includes the growth drivers, market trends and challenges faced by global healthcare CMO market. Company profiling of major players of healthcare CMO industry is also done in this report. The companies included are Catalent Pharma Solution, Recipharm and Aurobindo Pharma Ltd. Business overview, financial overview and business strategies for each company is provided.
Company Coverage
Contract manufacturing is a type of outsourcing in which a firm contacts with a third party (contract manufacturing organization) for the manufacturing of components of its product or whole of its product. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm.
A big or a mid-sized firm opt for a CMO mainly for two reasons, either it wants to shift (or reduce) its cost and focus to its core activities, or the manufacturing of its products require special or expert handing.
CMOs provide independent manufacturing services in healthcare sector also. Healthcare CMOs can be segmented into pharmaceutical CMOs and medical device CMOs. After the discovery of chemical formula of a new drug, the pharmaceutical CMOs are given the task of manufacturing it into a whole product, so that the pharmaceutical companies are able to sell it into the market under their brand name. Services offered by pharmaceutical CMOs can be divided into two main activities: primary manufacturing (Active Pharmaceutical Ingredients) and secondary manufacturing (Finished Dosage Formulation). Contract manufacturing for medical devices is one of the fastest growing segments of the medical device industry, as companies are in the race to bring new devices to the market.
From last few years, many pharmaceutical CMOs have included development part into their activities, apart from manufacturing of drugs and they are called contract development & manufacturing organizations (CDMOs). The market for pharmaceutical CMOs and CDMOs can neither be taken as same, nor be taken as completely distinct from each other. Also, these two markets cannot be combined together, as it will exaggerate the global pharmaceutical CMO market.
The global healthcare CMO market has recorded a continuous growth since last few years and is expected to follow the same trend in coming years. The main driving factors for this growth are rise in global pharmaceutical industry, increased need for outsourcing, increased approvals and outsourcing of NMEs, innovations and increased regulatory pressure on quality. Yet there are some challenges, which healthcare CMO industry faces, such as fragmented nature of market, less preference for outsourcing of profitable and biological drugs by big pharmaceutical companies.
This report named “Global Healthcare CMO Market: Trends & Opportunities (2015-2020)”, analyses the growth and sizing of global healthcare CMO market and its segments. This report provides the analysis of global healthcare CMO market by value and by segment.
The analysis of global medical device CMO market is done by value, by players and by cost structure and analysis of global pharmaceutical CMO is done by value and by segments. The global pharmaceutical CMO market by segments is analyzed in detail by providing analysis of each of its segment.
This report includes the analysis of global active pharmaceutical ingredient CMO market by value and analysis of finished dosage formulation CMO market by value, by revenue structure, by geographical approach and by dosage formulation.
This report also provides the analysis of global pharmaceutical CDMO market. This analysis includes the global pharmaceutical CDMO market by value, by players and by geography. The regional analysis of global pharmaceutical CDMO market is also done in this report. The regions included are United States of America, Europe, China and India.
This report also includes the growth drivers, market trends and challenges faced by global healthcare CMO market. Company profiling of major players of healthcare CMO industry is also done in this report. The companies included are Catalent Pharma Solution, Recipharm and Aurobindo Pharma Ltd. Business overview, financial overview and business strategies for each company is provided.
Company Coverage
- Catalent Pharma Solution
- Recipharm
- Aurobindo Pharma Limited
Contract manufacturing is a type of outsourcing in which a firm contacts with a third party (contract manufacturing organization) for the manufacturing of components of its product or whole of its product. A contract manufacturing organization (CMO) undertakes the production of product(s) under the brand name of another firm.
A big or a mid-sized firm opt for a CMO mainly for two reasons, either it wants to shift (or reduce) its cost and focus to its core activities, or the manufacturing of its products require special or expert handing.
CMOs provide independent manufacturing services in healthcare sector also. Healthcare CMOs can be segmented into pharmaceutical CMOs and medical device CMOs. After the discovery of chemical formula of a new drug, the pharmaceutical CMOs are given the task of manufacturing it into a whole product, so that the pharmaceutical companies are able to sell it into the market under their brand name. Services offered by pharmaceutical CMOs can be divided into two main activities: primary manufacturing (Active Pharmaceutical Ingredients) and secondary manufacturing (Finished Dosage Formulation). Contract manufacturing for medical devices is one of the fastest growing segments of the medical device industry, as companies are in the race to bring new devices to the market.
From last few years, many pharmaceutical CMOs have included development part into their activities, apart from manufacturing of drugs and they are called contract development & manufacturing organizations (CDMOs). The market for pharmaceutical CMOs and CDMOs can neither be taken as same, nor be taken as completely distinct from each other. Also, these two markets cannot be combined together, as it will exaggerate the global pharmaceutical CMO market.
The global healthcare CMO market has recorded a continuous growth since last few years and is expected to follow the same trend in coming years. The main driving factors for this growth are rise in global pharmaceutical industry, increased need for outsourcing, increased approvals and outsourcing of NMEs, innovations and increased regulatory pressure on quality. Yet there are some challenges, which healthcare CMO industry faces, such as fragmented nature of market, less preference for outsourcing of profitable and biological drugs by big pharmaceutical companies.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Healthcare CMOs
2.1.1 Pharmaceutical CMOs
2.1.2 Medical Device CMOs
2.2 Pharmaceutical Outsourcing
2.3 Pharmaceutical CMOs v/s CDMOs
3. GLOBAL HEALTHCARE CMO MARKET: AN ANALYSIS
3.1 Global Healthcare CMO Market: Sizing and Growth
3.1.1 Global Healthcare CMO Market by Value
3.1.2 Global Healthcare CMO Market by Segments
3.2 Global Medical Device CMO Market: Sizing and Growth
3.2.1 Global Medical Device CMO Market by Value
3.2.2 Global Medical Device CMO Market by Players
3.2.3 Global Medical Device CMO Market by Cost Structure
3.3 Global Pharmaceutical CMO Market: Sizing and Growth
3.3.1 Global Pharmaceutical CMO Market by Value
3.3.2 Global Pharmaceutical CMO Market by Segments
3.4 Global Active Pharmaceutical Ingredient (API) CMO Market: Sizing and Growth
3.4.1 Global Active Pharmaceutical Ingredient CMO Market by Value
3.5 Global Finished Dosage Formulation (FDF) CMO Market: Sizing and Growth
3.5.1 Global Finished Dosage Formulation CMO Market by Value
3.5.2 Global Finished Dosage Formulation CMO Market by Revenue Structure
3.5.3 Global Finished Dosage Formulation CMO Market by Geographical Approach
3.5.4 Global Finished Dosage Formulation CMO Market by Dose Formulation
4. GLOBAL PHARMACEUTICAL CDMO MARKET: AN ANALYSIS
4.1 Global Pharmaceutical CDMO Market: Sizing and Growth
4.1.1 Global Pharmaceutical CDMO Market by Value
4.1.2 Global Pharmaceutical CDMO Market by Geography
4.1.3 Global Pharmaceutical CDMO Market by Players
4.2 Global Pharmaceutical CDMO Market: A Regional Analysis
4.2.1 USA’s Pharmaceutical CDMO Market by Value
4.2.2 European Pharmaceutical CDMO Market by Value
4.2.3 China’s Pharmaceutical CDMO Market by Value
4.2.4 Indian Pharmaceutical CDMO Market by Value
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Growth in Global Pharmaceutical Industry
5.1.2 Drug Plants Divested by Big Pharmaceutical Companies
5.1.3 Outsourced Production
5.1.4 NMEs Requiring Special Handling
5.2 Challenges
5.2.1 Highly Fragmented Market
5.2.2 Less Preference for Outsourcing of Profitable Drugs
5.2.3 Manufacturing of Biological Drugs Less Outsourced
5.2.4 Investment in Own Production Facilities by Pharmaceutical Companies
5.3 Market Trends
5.3.1 Increased reliance on CMO/CDMO services
5.3.2 Innovation
5.3.3 Increased Regulatory Pressure on Quality
5.3.4 Change in Cost Base of Big Pharmaceutical Companies
5.3.5 Dosage Forms likely to be outsourced
6. COMPETITIVE LANDSCAPE
7. COMPANY PROFILES
7.1 Catalent Pharma Solutions Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Recipharm
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Aurobindo Pharma Limited
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
2. INTRODUCTION
2.1 Healthcare CMOs
2.1.1 Pharmaceutical CMOs
2.1.2 Medical Device CMOs
2.2 Pharmaceutical Outsourcing
2.3 Pharmaceutical CMOs v/s CDMOs
3. GLOBAL HEALTHCARE CMO MARKET: AN ANALYSIS
3.1 Global Healthcare CMO Market: Sizing and Growth
3.1.1 Global Healthcare CMO Market by Value
3.1.2 Global Healthcare CMO Market by Segments
3.2 Global Medical Device CMO Market: Sizing and Growth
3.2.1 Global Medical Device CMO Market by Value
3.2.2 Global Medical Device CMO Market by Players
3.2.3 Global Medical Device CMO Market by Cost Structure
3.3 Global Pharmaceutical CMO Market: Sizing and Growth
3.3.1 Global Pharmaceutical CMO Market by Value
3.3.2 Global Pharmaceutical CMO Market by Segments
3.4 Global Active Pharmaceutical Ingredient (API) CMO Market: Sizing and Growth
3.4.1 Global Active Pharmaceutical Ingredient CMO Market by Value
3.5 Global Finished Dosage Formulation (FDF) CMO Market: Sizing and Growth
3.5.1 Global Finished Dosage Formulation CMO Market by Value
3.5.2 Global Finished Dosage Formulation CMO Market by Revenue Structure
3.5.3 Global Finished Dosage Formulation CMO Market by Geographical Approach
3.5.4 Global Finished Dosage Formulation CMO Market by Dose Formulation
4. GLOBAL PHARMACEUTICAL CDMO MARKET: AN ANALYSIS
4.1 Global Pharmaceutical CDMO Market: Sizing and Growth
4.1.1 Global Pharmaceutical CDMO Market by Value
4.1.2 Global Pharmaceutical CDMO Market by Geography
4.1.3 Global Pharmaceutical CDMO Market by Players
4.2 Global Pharmaceutical CDMO Market: A Regional Analysis
4.2.1 USA’s Pharmaceutical CDMO Market by Value
4.2.2 European Pharmaceutical CDMO Market by Value
4.2.3 China’s Pharmaceutical CDMO Market by Value
4.2.4 Indian Pharmaceutical CDMO Market by Value
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Growth in Global Pharmaceutical Industry
5.1.2 Drug Plants Divested by Big Pharmaceutical Companies
5.1.3 Outsourced Production
5.1.4 NMEs Requiring Special Handling
5.2 Challenges
5.2.1 Highly Fragmented Market
5.2.2 Less Preference for Outsourcing of Profitable Drugs
5.2.3 Manufacturing of Biological Drugs Less Outsourced
5.2.4 Investment in Own Production Facilities by Pharmaceutical Companies
5.3 Market Trends
5.3.1 Increased reliance on CMO/CDMO services
5.3.2 Innovation
5.3.3 Increased Regulatory Pressure on Quality
5.3.4 Change in Cost Base of Big Pharmaceutical Companies
5.3.5 Dosage Forms likely to be outsourced
6. COMPETITIVE LANDSCAPE
7. COMPANY PROFILES
7.1 Catalent Pharma Solutions Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Recipharm
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Aurobindo Pharma Limited
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
TABLE OF FIGURES
Figure 1: Healthcare CMO Market by Segments
Figure 2: Pharmaceutical Outsourcing by Segments
Figure 3: Value Chain of a Drug
Figure 4: Global Healthcare CMO Market by Value; 2012-2014 (US$ Billion)
Figure 5: Global Healthcare CMO Market by Value; 2015-2020 (US$ Billion)
Figure 6: Global Healthcare CMO Market by Segments; 2014
Figure 7: Global Medical Device CMO Market by Value; 2012-2014 (US$ Billion)
Figure 8: Global Medical Device CMO Market by Value; 2015-2020 (US$ Billion)
Figure 9: Global Medical Device CMO Market by Players; 2014E
Figure 10: Global Medical Device CMO Market by Cost Structure; 2014
Figure 11: Global Pharmaceutical CMO Market by Value; 2012-2014 (US$ Billion)
Figure 12: Global Pharmaceutical CMO Market by Value; 2015-2020 (US$ Billion)
Figure 13: Global Pharmaceutical CMO Market by Segments; 2014
Figure 14: Global Active Pharmaceutical Ingredient CMO Market by Value; 2013-2020E (US$ Billion)
Figure 15: Global Finished Dosage Formulation CMO Market by Value; 2009-2014 (US$ Billion)
Figure 16: Global Finished Dosage Formulation CMO Market by Value; 2015-2020 (US$ Billion)
Figure 17: Global Finished Dosage Formulation CMO Market by Revenue Structure; 2014
Figure 18: Global Finished Dosage Formulation CMO Market by Geographical Approach; 2014
Figure 19: Global Finished Dosage Formulation CMO Market by Dose Formulation; 2014
Figure 20: Global Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 21: Global Pharmaceutical CDMO Market by Value; 2015-2019 (US$ Billion)
Figure 22: Global Pharmaceutical CDMO Market Share by Geography; 2014
Figure 23: Global Pharmaceutical CDMO Market Growth by Geography; 2011-2015 (CAGR, %)
Figure 24: Global Pharmaceutical CDMO Market Players by Sales Range; 2014 (US$ Million)
Figure 25: Global Pharmaceutical CDMO Market Players by Geography; 2014
Figure 26: USA’s Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 27: USA’s Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 28: European Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 29: European Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 30: China’s Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 31: China’s Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 32: Indian Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 33: Indian Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 34: Global Pharmaceutical Industry; 2007-2014 (US$ Billion)
Figure 35: Drug Plants Divested; 2000-2013 (avg.)
Figure 36: Outsourced Production; 2014
Figure 37: NME’s Approved and Outsourced; 2010-2014
Figure 38: Investment in Own Production Facilities by Pharmaceutical Companies; 2010-2014 (US$ Million)
Figure 39: Dosage Forms likely to be outsourced; 2014-2015
Figure 40: Catalent Pharma Solutions, Inc. Net Revenue; 2009-2014 (US$ Million)
Figure 41: Catalent Pharma Solutions Inc. Revenue by Segments; 2014
Figure 42: Recipharm Business Overview
Figure 43: Recipharm Net Sales; 2010-2014 (US$ Million)
Figure 44: Recipharm Net Sales by Segments; 2014
Figure 45: Recipharm Net Sales by Customers; 2014
Figure 46: Aurobindo Pharma Ltd. Revenue; 2010-2014 (US$ Million)
Figure 47: Aurobindo Pharma Ltd. Revenue by Segments; 2014
Figure 48: Aurobindo Pharma Ltd. Revenue by Geography
Table 1: Financial Comparison of Players in Global Healthcare CMO Market; 2014
Figure 1: Healthcare CMO Market by Segments
Figure 2: Pharmaceutical Outsourcing by Segments
Figure 3: Value Chain of a Drug
Figure 4: Global Healthcare CMO Market by Value; 2012-2014 (US$ Billion)
Figure 5: Global Healthcare CMO Market by Value; 2015-2020 (US$ Billion)
Figure 6: Global Healthcare CMO Market by Segments; 2014
Figure 7: Global Medical Device CMO Market by Value; 2012-2014 (US$ Billion)
Figure 8: Global Medical Device CMO Market by Value; 2015-2020 (US$ Billion)
Figure 9: Global Medical Device CMO Market by Players; 2014E
Figure 10: Global Medical Device CMO Market by Cost Structure; 2014
Figure 11: Global Pharmaceutical CMO Market by Value; 2012-2014 (US$ Billion)
Figure 12: Global Pharmaceutical CMO Market by Value; 2015-2020 (US$ Billion)
Figure 13: Global Pharmaceutical CMO Market by Segments; 2014
Figure 14: Global Active Pharmaceutical Ingredient CMO Market by Value; 2013-2020E (US$ Billion)
Figure 15: Global Finished Dosage Formulation CMO Market by Value; 2009-2014 (US$ Billion)
Figure 16: Global Finished Dosage Formulation CMO Market by Value; 2015-2020 (US$ Billion)
Figure 17: Global Finished Dosage Formulation CMO Market by Revenue Structure; 2014
Figure 18: Global Finished Dosage Formulation CMO Market by Geographical Approach; 2014
Figure 19: Global Finished Dosage Formulation CMO Market by Dose Formulation; 2014
Figure 20: Global Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 21: Global Pharmaceutical CDMO Market by Value; 2015-2019 (US$ Billion)
Figure 22: Global Pharmaceutical CDMO Market Share by Geography; 2014
Figure 23: Global Pharmaceutical CDMO Market Growth by Geography; 2011-2015 (CAGR, %)
Figure 24: Global Pharmaceutical CDMO Market Players by Sales Range; 2014 (US$ Million)
Figure 25: Global Pharmaceutical CDMO Market Players by Geography; 2014
Figure 26: USA’s Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 27: USA’s Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 28: European Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 29: European Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 30: China’s Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 31: China’s Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 32: Indian Pharmaceutical CDMO Market by Value; 2011-2014 (US$ Billion)
Figure 33: Indian Pharmaceutical CDMO Market by Value; 2015-2020 (US$ Billion)
Figure 34: Global Pharmaceutical Industry; 2007-2014 (US$ Billion)
Figure 35: Drug Plants Divested; 2000-2013 (avg.)
Figure 36: Outsourced Production; 2014
Figure 37: NME’s Approved and Outsourced; 2010-2014
Figure 38: Investment in Own Production Facilities by Pharmaceutical Companies; 2010-2014 (US$ Million)
Figure 39: Dosage Forms likely to be outsourced; 2014-2015
Figure 40: Catalent Pharma Solutions, Inc. Net Revenue; 2009-2014 (US$ Million)
Figure 41: Catalent Pharma Solutions Inc. Revenue by Segments; 2014
Figure 42: Recipharm Business Overview
Figure 43: Recipharm Net Sales; 2010-2014 (US$ Million)
Figure 44: Recipharm Net Sales by Segments; 2014
Figure 45: Recipharm Net Sales by Customers; 2014
Figure 46: Aurobindo Pharma Ltd. Revenue; 2010-2014 (US$ Million)
Figure 47: Aurobindo Pharma Ltd. Revenue by Segments; 2014
Figure 48: Aurobindo Pharma Ltd. Revenue by Geography
Table 1: Financial Comparison of Players in Global Healthcare CMO Market; 2014
